Cancer screening

Doctor-patient discussions neglect potential harms of lung cancer screening, study finds

Although national guidelines advise doctors to discuss the benefits and harms of lung cancer screening with high-risk patients because of a high rate of false positives and other factors, those conversations aren’t happening the way they should be, according to a study by researchers from the University of North Carolina Lineberger Comprehensive Cancer Center. Lung […]

Biotechnology cancer Clinical Trials Uncategorized

Brain metastases common and difficult to treat in ROS1 lung cancer

Increasingly, doctors are treating lung cancer based on the genetic rearrangements driving the disease. For example, cancers that are driven by changes in the genes ALK, EGFR, and ROS1 can now all be paired with drugs that target these specific changes. However, these cancers are not only dangerous in the lung where they appear, but […]

Biotechnology cancer Cell Therapy

Drug Reduces Size of Some Lung Cancer Tumors, Relapse Rate After Surgery

A drug given to early stage lung cancer patients before they undergo surgery showed major tumor responses in the removed tumor and an increase in anti-tumor T-cells that remained after the tumor was removed, which resulted in fewer relapse cases in the patients. The research teams at the Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, […]

cancer Cancer Discovery

Novel Clinical Tool to Predict Patient Survival Rate and Treatment Outcomes for Early-Stage Lung Cancer

A team of researchers, led by Professor Lim Chwee Teck from the Department of Biomedical Engineering at the National University of Singapore (NUS) and NUS PhD candidate Ms Lim Su Bin, has leveraged open source data to develop a personalised risk assessment tool that can potentially predict patient survival rate and treatment outcomes of early-stage […]

Biotechnology cancer Cancer Discovery Uncategorized

Identifying a New Therapeutic Target for the Most Common Type of Lung Cancer

Research by Rutgers Cancer Institute of New Jersey investigators has identified novel functions of the superoxide dismutase 1 (SOD1) enzyme providing support that it could serve as a therapeutic target in the most common type of lung cancer. Results of the work are being presented as part of a poster session at the American Association […]

Biotechnology cancer Cell Therapy Clinical Trials Immunotherapies

Molecular Inhibitors Can Boost Natural Tumor Suppression to Fight Lung Cancer and Mesothelioma

Inhibition of the oncogenic kinase AKT, a key protein governing the cell cycle, was found to arrest cancer cell proliferation and triggered their programmed death by apoptosis. The study, published today in Oncogene, represents significant progress in the clinical translation of previous basic scientific discoveries. “Understanding the molecular features that govern cancer cell behavior is […]

Pharmaceutical Business News

FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing

The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation). “This is the first treatment approved for stage III […]

cancer Cancer Discovery

Early Evidence of Efficacy and Safety Seen in Novel Targeted Immunotherapy

An immune-oncology focused biotechnology company, BriaCell, has provided a clinical update on its lead immunotherapy drug for advanced breast cancer. BriaCell provided further update on its ongoing clinical trial of Bria-IMT™ according to Protocol WRI-GEV-007 (listed in ClinicalTrials.gov as NCT03066947).  Six patients have received inoculations since the trial began in early 2017, with the observation […]

cancer

Placental Cells Significantly Inhibit Cancer Cell Growth in Newly Published Study

According to the peer-reviewed article in the journal Scientific Reports, placenta-derived cells called PLX cells, exhibit a strong inhibitory effect on various lines of breast, colorectal, kidney, liver, lung, muscle and skin cancers. The research was conducted over more than two years by Pluristem Therapeutics, Inc., a Haifa-based biotechnology company. The article titled “Human Placental-Derived Adherent […]

Biotechnology cancer Cell Therapy Immunotherapies Prodrug

2-Drug Combination May Boost Immunotherapy Responses in Lung Cancer Patients

Johns Hopkins Kimmel Cancer Center researchers and colleagues have identified a novel drug combination therapy that could prime nonsmall cell lung cancers to respond better to immunotherapy. These so-called epigenetic therapy drugs, used together, achieved robust anti-tumor responses in human cancer cell lines and mice. During the study, published Nov. 30, 2017, in the journal […]

Biotechnology cancer Gene Therapy Prodrug rare diseases

Deadly Lung Cancers Are Driven by Multiple Genetic Changes

Blood-Based Cancer Tests Reveal Complex Genomic Landscape of Non-Small Cell Lung Cancers A new UC San Francisco–led study challenges the dogma in oncology that most cancers are caused by one dominant “driver” mutation that can be treated in isolation with a single targeted drug. Instead, the new research finds one of the world’s most deadly […]

cancer

Research suggests possible new treatment for EGFR-positive lung cancer

Findings from a phase III clinical trial point to a potential new treatment for patients newly diagnosed with advanced, epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). Compared to the EGFR inhibitor gefitinib (Iressa), one of the standard targeted medicines for this disease, second-generation EGFR inhibitor dacomitinib delayed cancer growth by a median […]

cancer Cancer Discovery Gene Therapy

Thorough Genotyping and Repurposed Drugs Key to Treating Small-Cell Lung Cancer, says Cancer Expert

Small cell lung cancer (SCLC) is an aggressive disease characterized by quick growth and spread. While there has been a gradual decrease in incidence of SCLC in recent years, likely reflecting the decreased prevalence of tobacco use, little progress has been made in treating SCLC due to its complex pathogenesis. The majority of patients, including […]